EXPERT INTERVIEW WITH DR JÜRGEN FREVERT
DR. JÜRGEN FREVERT
“I’m proud that we succeeded in developing a pure product”
Dr Jürgen Frevert could be described as the father of XEOMIN®. He first heard of the toxin more than 30 years ago, when, as a post-doctoral researcher, he was tasked with purifying botulinum toxin type A.
XEOMIN® IS PART OF A LIFETIME OF BOTULINUM TOXIN RESEARCH
‘I’m proud that we succeeded in developing a highly purified neurotoxin, the only product currently on the market that is free of other bacterial proteins and which is stable at room temperature’, Dr Frevert enthuses.
‘As a basic scientist, a biochemist, it is very satisfying to have developed a product, with my own hands, that has been used in over 1.6 million patients in numerous indications. And it is a high-quality product – of all the patients treated to date, none have developed neutralising antibodies or have become secondary non-responders, allowing patients to benefit from repeat treatments.
Not only is the neurotoxin the only bacterial protein present in each vial of XEOMIN®, the manufacturing process is so exquisitely controlled that the purified neurotoxin does not lose any activity. This means that, whilst having the lowest amount of neurotoxin in the vial, XEOMIN® has the highest specific potency compared with two other commercially available botulinum toxin products’ 1.
‘I knew that complexing proteins could stimulate the immune system to produce antibodies that neutralise the neurotoxin’ Dr Frevert reveals. ‘I wanted to produce a new formulation of the neurotoxin without the complexing proteins that other available formulations contain. Then patients only get what they need, just the highly purified neurotoxin, and therefore the risk of antibody formation is minimised’.
Frevert J. Drugs R D 2010;10:67–73.